Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 235Breast Neoplasms 233Prostatic Neoplasms 170Multiple Myeloma 151Neoplasms 134Colorectal Neoplasms 126Leukemia, Myeloid, Acute 121Lung Neoplasms 108Neoplasm Metastasis 101Squamous Cell Carcinoma of Head and Neck 94Carcinoma, Hepatocellular 88Melanoma 86Lymphoma 82Triple Negative Breast Neoplasms 77Pancreatic Neoplasms 76Ovarian Neoplasms 71Sarcoma 68Carcinoma, Renal Cell 64Recurrence 63Lymphoma, Large B-Cell, Diffuse 63Brain Neoplasms 63Precursor Cell Lymphoblastic Leukemia-Lymphoma 60Head and Neck Neoplasms 57Lymphoma, Non-Hodgkin 56Stomach Neoplasms 54Leukemia, Lymphocytic, Chronic, B-Cell 54Endometrial Neoplasms 53Hematologic Neoplasms 52Urinary Bladder Neoplasms 50Small Cell Lung Carcinoma 49

Interventions

pembrolizumab 1Nivolumab 1Immune Checkpoint Inhibitors 1DEAE-Dextran 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Oligoprogressive × 90 days × Clear all
NCT05846659 2026-05-15

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

ImmuneSensor Therapeutics Inc.

Phase 2 Terminated
16 enrolled 13 charts

Oligoprogressive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡